From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling
Abstract Receptor-targeted polypharmacology is emerging as a promising strategy for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. GLP-1–GIP–lanifibranor, a unimolecular conjugate combining GLP-1R/GIPR co-agonism with pan-PPAR activation, enables rec...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BioMed Central
2026-06-01
|
| Seria: | Cardiovascular Diabetology. Endocrinology Reports |
| Dostęp online: | https://doi.org/10.1186/s40842-026-00321-4 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|